Preclinical studies have shown that the Bcl-2/Bcl-xl dual target inhibitor ABT-737 significantly enhances the anti-tumor effects of chemotherapy and radiotherapy and is effective in a variety of hematological and solid tumors. The gene discussed is BCL2L1; the disease is neoplasm.